Glaukos Corporation Logo

Glaukos Corporation

GKOS

(0.5)
Stock Price

122,31 USD

-21.8% ROA

-27.81% ROE

-33.44x PER

Market Cap.

4.336.332.456,00 USD

80.35% DER

0% Yield

-42.79% NPM

Glaukos Corporation Stock Analysis

Glaukos Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Glaukos Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a reasonable amount of debt compared to its ownership (80%), suggesting a balanced financial position and a moderate level of risk.

2 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (114) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

3 ROE

The stock's ROE indicates a negative return (-25.8%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-21.8%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (6.53x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Glaukos Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Glaukos Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Glaukos Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Glaukos Corporation Revenue
Year Revenue Growth
2013 20.946.000
2014 45.587.000 54.05%
2015 71.700.000 36.42%
2016 114.397.000 37.32%
2017 159.254.000 28.17%
2018 181.278.000 12.15%
2019 236.984.000 23.51%
2020 224.959.000 -5.35%
2021 294.011.000 23.49%
2022 282.862.000 -3.94%
2023 312.192.000 9.39%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Glaukos Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2013 15.511.000
2014 19.205.000 19.23%
2015 25.047.000 23.32%
2016 29.223.000 14.29%
2017 44.225.000 33.92%
2018 49.676.000 10.97%
2019 72.053.000 31.06%
2020 85.392.000 15.62%
2021 110.999.000 23.07%
2022 123.271.000 9.96%
2023 133.204.000 7.46%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Glaukos Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 0
2014 0 0%
2015 43.961.000 100%
2016 64.756.000 32.11%
2017 96.260.000 32.73%
2018 119.529.000 19.47%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Glaukos Corporation EBITDA
Year EBITDA Growth
2013 -13.028.000
2014 -8.937.000 -45.78%
2015 -10.214.000 12.5%
2016 5.130.000 299.1%
2017 45.000 -11300%
2018 -13.002.000 100.35%
2019 -47.471.000 72.61%
2020 -118.199.000 59.84%
2021 -65.895.000 -79.37%
2022 -104.709.000 37.07%
2023 -108.036.000 3.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Glaukos Corporation Gross Profit
Year Gross Profit Growth
2013 18.411.000
2014 34.169.000 46.12%
2015 58.712.000 41.8%
2016 98.220.000 40.22%
2017 138.204.000 28.93%
2018 156.203.000 11.52%
2019 198.396.000 21.27%
2020 133.240.000 -48.9%
2021 227.384.000 41.4%
2022 213.883.000 -6.31%
2023 238.152.000 10.19%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Glaukos Corporation Net Profit
Year Net Profit Growth
2013 -12.639.000
2014 -12.126.000 -4.23%
2015 -37.241.000 67.44%
2016 4.522.000 923.55%
2017 -92.000 5015.22%
2018 -12.951.000 99.29%
2019 15.424.000 183.97%
2020 -120.348.000 112.82%
2021 -49.593.000 -142.67%
2022 -99.195.000 50%
2023 -121.776.000 18.54%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Glaukos Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -1
2014 0 0%
2015 -2 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 -3 100%
2021 -1 -100%
2022 -2 50%
2023 -3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Glaukos Corporation Free Cashflow
Year Free Cashflow Growth
2013 -14.157.000
2014 -7.975.000 -77.52%
2015 -3.065.000 -160.2%
2016 6.031.000 150.82%
2017 19.197.000 68.58%
2018 8.549.000 -124.55%
2019 -5.093.000 267.86%
2020 -29.923.000 82.98%
2021 -23.077.000 -29.67%
2022 -63.348.000 63.57%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Glaukos Corporation Operating Cashflow
Year Operating Cashflow Growth
2013 -13.305.000
2014 -7.107.000 -87.21%
2015 -2.188.000 -224.82%
2016 12.309.000 117.78%
2017 25.508.000 51.74%
2018 18.864.000 -35.22%
2019 -369.000 5212.2%
2020 -22.988.000 98.39%
2021 24.708.000 193.04%
2022 -33.083.000 174.68%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Glaukos Corporation Capital Expenditure
Year Capital Expenditure Growth
2013 852.000
2014 868.000 1.84%
2015 877.000 1.03%
2016 6.278.000 86.03%
2017 6.311.000 0.52%
2018 10.315.000 38.82%
2019 4.724.000 -118.35%
2020 6.935.000 31.88%
2021 47.785.000 85.49%
2022 30.265.000 -57.89%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Glaukos Corporation Equity
Year Equity Growth
2013 -141.298.000
2014 -151.299.000 6.61%
2015 95.191.000 258.94%
2016 117.274.000 18.83%
2017 138.202.000 15.14%
2018 173.860.000 20.51%
2019 673.272.000 74.18%
2020 667.449.000 -0.87%
2021 587.151.000 -13.68%
2022 530.005.000 -10.78%
2023 477.659.000 -10.96%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Glaukos Corporation Assets
Year Assets Growth
2013 30.877.000
2014 26.021.000 -18.66%
2015 116.661.000 77.7%
2016 134.371.000 13.18%
2017 165.836.000 18.97%
2018 206.970.000 19.87%
2019 818.400.000 74.71%
2020 1.005.502.000 18.61%
2021 1.049.698.000 4.21%
2022 1.002.383.000 -4.72%
2023 948.634.000 -5.67%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Glaukos Corporation Liabilities
Year Liabilities Growth
2013 179.919.000
2014 186.925.000 3.75%
2015 21.470.000 -770.63%
2016 17.097.000 -25.58%
2017 27.634.000 38.13%
2018 33.110.000 16.54%
2019 145.128.000 77.19%
2020 338.053.000 57.07%
2021 462.547.000 26.91%
2022 472.378.000 2.08%
2023 470.975.000 -0.3%

Glaukos Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.24
Net Income per Share
-2.66
Price to Earning Ratio
-33.44x
Price To Sales Ratio
14.28x
POCF Ratio
-100.44
PFCF Ratio
-67.8
Price to Book Ratio
9.06
EV to Sales
15.19
EV Over EBITDA
-47.11
EV to Operating CashFlow
-107.09
EV to FreeCashFlow
-72.1
Earnings Yield
-0.03
FreeCashFlow Yield
-0.01
Market Cap
4,34 Bil.
Enterprise Value
4,61 Bil.
Graham Number
24.22
Graham NetNet
-2.48

Income Statement Metrics

Net Income per Share
-2.66
Income Quality
0.44
ROE
-0.26
Return On Assets
-0.14
Return On Capital Employed
-0.15
Net Income per EBT
1.01
EBT Per Ebit
1.04
Ebit per Revenue
-0.41
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.46
Stock Based Compensation to Revenue
0.1
Gross Profit Margin
0.76
Operating Profit Margin
-0.41
Pretax Profit Margin
-0.42
Net Profit Margin
-0.43

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.88
Free CashFlow per Share
-1.31
Capex to Operating CashFlow
0.49
Capex to Revenue
-0.07
Capex to Depreciation
-0.81
Return on Invested Capital
-0.13
Return on Tangible Assets
-0.22
Days Sales Outstanding
47.28
Days Payables Outstanding
51.43
Days of Inventory on Hand
196.47
Receivables Turnover
7.72
Payables Turnover
7.1
Inventory Turnover
1.86
Capex per Share
-0.43

Balance Sheet

Cash per Share
6,18
Book Value per Share
9,81
Tangible Book Value per Share
2.51
Shareholders Equity per Share
9.81
Interest Debt per Share
8.16
Debt to Equity
0.8
Debt to Assets
0.4
Net Debt to EBITDA
-2.81
Current Ratio
5.95
Tangible Asset Value
0,12 Bil.
Net Current Asset Value
-0,07 Bil.
Invested Capital
0.8
Working Capital
0,33 Bil.
Intangibles to Total Assets
0.37
Average Receivables
0,04 Bil.
Average Payables
0,01 Bil.
Average Inventory
39614000
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Glaukos Corporation Dividends
Year Dividends Growth

Glaukos Corporation Profile

About Glaukos Corporation

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

CEO
Mr. Thomas William Burns
Employee
907
Address
229 Avenida Fabricante
San Clemente, 92672

Glaukos Corporation Executives & BODs

Glaukos Corporation Executives & BODs
# Name Age
1 Ms. Jane E. Rady
Senior Vice President of Corporate Strategy & Business Development
70
2 Mr. Joseph E. Gilliam
President & Chief Operating Officer
70
3 Dr. Tomas Navratil Ph.D.
Chief Development Officer
70
4 Ms. Diana A. Scherer
Vice President of Compliance & Deputy General Counsel
70
5 Ms. Michele M. Allegretto
Senior Vice President of Human Resources
70
6 Mr. Christopher William Lewis
Vice President of Investor Relations & Corporate Affairs
70
7 Mr. Thomas William Burns
Chairman & Chief Executive Officer
70
8 Mr. Alex R. Thurman
Senior Vice President & Chief Financial Officer
70
9 Mr. Chris M. Calcaterra
Executive Vice President of Global Commercial Operations
70
10 Dr. Mory Gharib Ph.D.
Co-Founder
70

Glaukos Corporation Competitors

CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Paragon 28, Inc. Logo
Paragon 28, Inc.

FNA

(1.5)
NuVasive, Inc. Logo
NuVasive, Inc.

NUVA

(1.0)
Heska Corporation Logo
Heska Corporation

HSKA

(1.0)
Bruker Corporation Logo
Bruker Corporation

BRKR

(2.5)
Nevro Corp. Logo
Nevro Corp.

NVRO

(1.0)
Surmodics, Inc. Logo
Surmodics, Inc.

SRDX

(0.8)